Well this is encouraging...for both the selection per seand the exposure.
-----------------
Tuesday October 17, 12:49 pm Eastern Time
Press Release
SOURCE: Hypertension Diagnostics, Inc.
Hypertension Diagnostics' HDI/PulseWave(TM) CR-2000 Research System Included in NIH/NHLBI 10-Year Multi-Ethnic Study of Atherosclerosis
ST. PAUL, Minn., Oct. 17 /PRNewswire/ -- Hypertension Diagnostics, Inc. (Nasdaq: HDII; HDIIW; HDIIU) announced the inclusion of its HDI/PulseWave(TM) CR-2000 Research CardioVascular Profiling System in the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) multi-site Multi-Ethnic Study of Atherosclerosis (MESA).
MESA is a 10-year prospective study of the characteristics of subclinical cardiovascular disease (disease detected before it has produced signs and symptoms) that predict progression to clinically overt cardiovascular disease in a diverse and representative population-based sample of men and women aged 35 to 84. During the initial 2-year phase of MESA, it is anticipated that each of approximately 6,500 study participants will have his or her Large and Small Artery Elasticity Index determined using the HDI/PulseWave(TM) CR-2000 Research System, along with other subclinical cardiovascular disease measurements and measurements of possible clinical disease precursors. Over the next six years of the study, the enrollees will be followed to determine changes in subclinical disease as well as for cardiovascular morbidity and mortality.
``We are pleased that NHLBI and the MESA Investigators have elected to incorporate the HDI/PulseWave(TM) CR-2000 Research System\ in this landmark study,'' said Greg H. Guettler, President of HDI. As noted in the original Request for Proposal (RFP) for MESA, NHLBI stated, ``Vascular stiffness and endothelial function are additional new non-invasive measures of early functional changes in the vasculature with strong relationships to existing disease, risk factor exposure, and effective treatment.''
Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2000 Annual Report on Form 10-KSB under the caption ``Risk Factors,'' as well as others not now anticipated.
SOURCE: Hypertension Diagnostics, Inc.
------------------
biz.yahoo.com |
